Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Senti Biosciences (NASDAQ:SNTI): What's Next for Its Gene-Circuit Cell Therapy Platform?

● Senti's lead candidate, SENTI-202, is a gene-circuit CAR-NK cell therapy aimed at relapsed or refractory acute myeloid leukemia.

Vinay Lochav | 27 August 2026

Can a Pivotal Liver Cancer Readout Turn Around Tvardi Therapeutics (NASDAQ:TVRD)?

Tvardi Therapeutics (NASDAQ:TVRD) is at the stage every clinical biotech must eventually reach: the point where pipeline promise meets the hard arithmetic of cash and catalysts. The company, which develops orally available small-molecule STAT3 inhibitors, updated investors in mid-August 2026 with aBusinessreview that laid …

Vinay Lochav | 27 August 2026

HCW Biologics (NASDAQ:HCWB): Can Its Inflammation Pipeline Keep Building Momentum?

HCW Biologics (NASDAQ:HCWB) is an immunotherapy company developing novel biologics aimed at chronic inflammation and autoimmune diseases. The company reported second-quarter 2026 results with an update on an early-stage program, following a period of building progress.

Vinay Lochav | 27 August 2026

Keros Therapeutics (NASDAQ:KROS): Does a Restructured Pipeline Offer a Path Forward?

Keros Therapeutics (NASDAQ:KROS) has undergone a wrenching reset, discontinuing development of a lead cardiopulmonary drug after safety concerns and restructuring around a different candidate. Understanding what the company is now focused on, and what it discontinued, is essential to assessing the shares.

Vinay Lochav | 27 August 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX): Can Its Phase 3 Wins Translate Into a Commercial Path?

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been generating the kind of late-stage clinical data that can define a biotech's future, reporting positive Phase 3 results for its lead drug across multiple inflammatory diseases. With a differentiated therapy and a string of successful trials, investors are watching …

Vinay Lochav | 27 August 2026

InspireMD (NASDAQ:NSPR): Can the CGuard Stent System Overcome Commercialization Hurdles?

● The company reported 30-day results from the CGUARDIANS II clinical trial of its CGuard Prime implant.

Vinay Lochav | 27 August 2026

PDS Biotechnology (NASDAQ:PDSB) Stuck in Neutral: Could the Next Catalyst Change Everything?

●Phase 3 trial underway:PDS Biotechnology is running the VERSATILE-003 trial evaluating its Versamune HPV immunotherapy in HPV16-positive head and neck cancer.

Vinay Lochav | 27 August 2026

Reviva Pharmaceuticals (OTC:RVPH) Moves Higher: Is a Breakout Setting Up?

●Positive extension data:Reviva reported a full dataset from a one-year Phase 3 RECOVER open-label extension study evaluating brilaroxazine in schizophrenia.

Vinay Lochav | 27 August 2026

Is Skye Bioscience's (NASDAQ:SKYE) $125 Million Redx Deal the Start of a Bigger Obesity Story?

Skye Bioscience (NASDAQ:SKYE) is positioning itself for a bigger role in the crowded obesity-drug arena, and a mid-August 2026 transaction has given the effort freshCapitaland a new strategic dimension. The clinical-stage company, whose lead program targets a novel mechanism for weight management, announced a …

Vinay Lochav | 27 August 2026
Support

Hi! How can we help you today?

Loading…